EchoIQ Limited (AU:EIQ) has released an update.
Echo IQ Limited has completed a crucial U.S. Reader Study, a significant step in the FDA clearance process for their AI detection tool for aortic stenosis, and considers this information materially price-sensitive. The company has been transparent about the study’s progress in previous reports and has adhered to its Trading Policy as confirmed by the Board’s approval. Amidst these developments, Mr. Rothwell has stepped down from his role following concerns about his cultural fit, with Mr. Grover taking over as interim CEO.
For further insights into AU:EIQ stock, check out TipRanks’ Stock Analysis page.
